These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27684457)

  • 1. Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials.
    Du C; Ren J; Zhang R; Xin T; Li Z; Zhang Z; Xu X; Pang Q
    Med Sci Monit; 2016 Sep; 22():3486-3492. PubMed ID: 27684457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis.
    Alnahhas I; Alsawas M; Rayi A; Palmer JD; Raval R; Ong S; Giglio P; Murad MH; Puduvalli V
    Neurooncol Adv; 2020; 2(1):vdaa082. PubMed ID: 33150334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
    Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
    J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Significance of O
    Zhao YH; Wang ZF; Cao CJ; Weng H; Xu CS; Li K; Li JL; Lan J; Zeng XT; Li ZQ
    Front Neurol; 2018; 9():127. PubMed ID: 29619003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
    Raizer JJ; Giglio P; Hu J; Groves M; Merrell R; Conrad C; Phuphanich S; Puduvalli VK; Loghin M; Paleologos N; Yuan Y; Liu D; Rademaker A; Yung WK; Vaillant B; Rudnick J; Chamberlain M; Vick N; Grimm S; Tremont-Lukats IW; De Groot J; Aldape K; Gilbert MR;
    J Neurooncol; 2016 Jan; 126(1):185-192. PubMed ID: 26476729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study.
    Chen J; Wang T; Liu W; Qiu H; Zhang N; Chen X; Ding X; Zhang L
    Front Oncol; 2022; 12():1000501. PubMed ID: 36483042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis.
    Chen Y; Hu F; Zhou Y; Chen W; Shao H; Zhang Y
    Arch Med Res; 2013 May; 44(4):281-90. PubMed ID: 23608672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.
    Omuro A; Reardon DA; Sampson JH; Baehring J; Sahebjam S; Cloughesy TF; Chalamandaris AG; Potter V; Butowski N; Lim M
    Neurooncol Adv; 2022; 4(1):vdac025. PubMed ID: 35402913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
    Brandes AA; Tosoni A; Franceschi E; Sotti G; Frezza G; Amistà P; Morandi L; Spagnolli F; Ermani M
    J Clin Oncol; 2009 Mar; 27(8):1275-9. PubMed ID: 19188675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma.
    Faye MD; Easaw J; De Robles P; Agnihotram R; Torres-Vasquez A; Lamonde F; Petrecca K; Owen S; Panet-Raymond V; Shenouda G; Souhami L; Azam M; Hossain B; Alkass J; Sabri S; Abdulkarim B
    Neurooncol Adv; 2023; 5(1):vdad106. PubMed ID: 37771465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
    Zhao H; Wang S; Song C; Zha Y; Li L
    World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
    Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
    Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.